PAREKH RAJESH B 4
4 · Eloxx Pharmaceuticals, Inc. · Filed May 17, 2021
Insider Transaction Report
Form 4
PAREKH RAJESH R
Director
Transactions
- Purchase
Common Stock
2021-05-13$1.35/sh+84,776$114,448→ 171,807 total(indirect: See footnote) - Purchase
Common Stock
2021-05-13$1.35/sh+2,381,890$3,215,552→ 4,827,129 total(indirect: See footnote)
Footnotes (3)
- [F1]Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that is expected to close on May 18, 2021.
- [F2]Held directly by Advent Life Sciences LLP. The Reporting Person is a general partner of Advent Life Sciences LLP. The Reporting Person disclaims beneficial ownership of the reported shares, except to the extent of any pecuniary interest therein.
- [F3]Held directly by Advent Life Sciences Fund II LP. Advent Life Sciences LLP is the manager of Advent Life Sciences Fund II LP and the Reporting Person is a general partner of Advent Life Sciences LLP. The Reporting Person disclaims beneficial ownership of the reported shares, except to the extent of any pecuniary interest therein.